Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A
Authors:
- W. WegertWWW. Wegert
- M. KrauseMKM. Krause
- C. Escuriola-EttinghausenCEC. Escuriola-Ettinghausen
- A. SiegemundASA. Siegemund
- S. PetrosSPS. Petros
- T. ScholzTST. Scholz
- I. ScharrerISI. Scharrer
- W. KreuzWKW. Kreuz
- L. EngelmannLEL. Engelmann
- C. M. KirchmaierCKC. M. Kirchmaier
- 1 January 2006
- journal article
- clinical trial
- Published by Taylor & Francis in Platelets
- Vol. 17 (6) , 378-384
Abstract
FVIII therapy for haemophilia A is safe and effective, with the problem of individually sufficient efficacy unsettled. Routine one-stage clotting assays and tests employing chromogenic substrates poorly detect individual haemostatic effects of FVIII due to artificial test conditions. In particular, the use of cell-free and diluted plasma samples neglect the crucial role of platelets for thrombin and fibrin formation. To optimize FVIII substitution therapy, we measured in 40 patients with severe to mild haemophilia A before and after FVIII substitution the FVIII activity in cell-free plasma samples using a one-stage clotting assay as well a chromogenic substrate assay and compared the data with those obtained with cell-based coagulation tests, i.e. thrombin generation in platelet-rich plasma (PRP) and thromboelastography (TEG) in samples of citrated whole blood (WB). To determine the maximum ex vivo haemostatic effect we added 1 unit/ml of FVIII to samples of PRP and WB and measured the maximum thrombin generation in the thrombin generation test (TGT) and the maximum clot firmness (MCF) in TEG. After FVIII substitution we observed a nearly linear relation between the individual FVIII activities administered to the patients and the activities measured in the plasma samples. However, data obtained with TGT and TEG revealed a high inter-individual variation and a very poor correlation to the administered FVIII activity. Actually, it could be shown that FVIII substitution yielding in a FVIII plasma activity of about 30% is sufficient to get an ex vivo haemostatic effect of more that 90% as measured by maximum thrombin generation and MCF. FVIII substitution up to a plasma activity of more than 90% did not further enhance the haemostatic effect. Our data clearly demonstrate that the haemostatic effect of FVIII is not only dependent on the activity that is measured in plasma but also depends on the interplay between coagulation and blood cells, in particular with platelets. The use of cell-based coagulation tests such us TGT or TEG may help to optimize FVIII therapy by determining the individual FVIII dosage that produces a maximum haemostatic effect.Keywords
This publication has 20 references indexed in Scilit:
- Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIaPlatelets, 2005
- Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assaysJournal of Thrombosis and Haemostasis, 2004
- Thrombin generation: phenotypic quantitationJournal of Thrombosis and Haemostasis, 2004
- A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standardsJournal of Thrombosis and Haemostasis, 2003
- Platelet Activation and Blood CoagulationThrombosis and Haemostasis, 2002
- Measurement of factor VIII activity of B-domain deleted recombinant factor VIIISeminars in Hematology, 2001
- The Effect of DDAVP Infusion on Thrombin Generation in Platelet-rich Plasma of von Willebrand Type 1 and in Mild Haemophilia A PatientsThrombosis and Haemostasis, 2000
- In vivo recovery with products of very high purity — assay discrepanciesHaemophilia, 1998
- Haemophilia treatment protocols around the world: towards a consensusHaemophilia, 1998
- Variability in platelet procoagulant activity in healthy volunteersThrombosis Research, 1996